Related Experiment Video
Updated: Jul 11, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
[Adjuvant treatment of breast cancer. Endocrine therapy]
Henning T Mouridsen1, Jørn Andersen
1Rigshospitalet, Finsencentret, Onkologisk Klinisk 5074, København Ø. henning.mouridsen@rh.hosp.dk
Abstract:
For women with steroid receptor-positive breast cancers, endocrine therapy has proven to be a major component of adjuvant therapy reducing the risk of recurrence and death. The selective estrogen-receptor modulator (SERM) tamoxifen has been well established as safe and effective in the adjuvant care of both pre- and postmenopausal women. For premenopausal women, ovarian suppression is an important option to be considered. Additionally, aromatase inhibitors have recently demonstrated further benefits in postmenopausal women. The ideal sequencing of treatment with tamoxifen and/or an aromatase inhibitor is the subject of several ongoing studies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Endocrine Signaling
Endocrine Signaling
Treatment Resistant Cancers
Treatment Resistent Cancers